Review



recombinant myostatin  (PeproTech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    PeproTech recombinant myostatin
    A) Schematic of the multi-hit MASLD model in iPSC-derived hepatocytes and respective injury trajectories. B) Representative fluorescence microscopic images of HLCs cumulatively exposed to Oleic Acid and Palmitic Acid (OA/PA), <t>Resistin</t> and Myostatin (Res/Myo) and peripheral blood mono-nuclear cells (PBMCs) indicated as respective injury hit models and stained with LipidSpot and Mitotracker Red. C) Quantification of steatotic area normalized to respective Mitotracker area in percent. Dots represent independent wells. Tukey-Post Hoc analysis to test for significance. D) Quantification of Mitotracker signal intensity, normalized to untreated cells. Dots represent independent wells. Wilcoxon test to test for significance. E) Number of differentially expressed genes from bulk RNAsequencing in different injury conditions compared to untreated cells F) Pooled injury curve fits including the scaled injury parameters steatosis, mitochondrial membrane potential alterations and number of DEGs from RNA sequencing. Injury scores were normalized to PNPLA3-wt conditions for which no hits represented 0% and all hits represent 100%.
    Recombinant Myostatin, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant myostatin/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant myostatin - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Dissecting compounded hepatocyte injury in a model of MASLD progression from human induced pluripotent stem cells"

    Article Title: Dissecting compounded hepatocyte injury in a model of MASLD progression from human induced pluripotent stem cells

    Journal: bioRxiv

    doi: 10.1101/2024.10.10.617610

    A) Schematic of the multi-hit MASLD model in iPSC-derived hepatocytes and respective injury trajectories. B) Representative fluorescence microscopic images of HLCs cumulatively exposed to Oleic Acid and Palmitic Acid (OA/PA), Resistin and Myostatin (Res/Myo) and peripheral blood mono-nuclear cells (PBMCs) indicated as respective injury hit models and stained with LipidSpot and Mitotracker Red. C) Quantification of steatotic area normalized to respective Mitotracker area in percent. Dots represent independent wells. Tukey-Post Hoc analysis to test for significance. D) Quantification of Mitotracker signal intensity, normalized to untreated cells. Dots represent independent wells. Wilcoxon test to test for significance. E) Number of differentially expressed genes from bulk RNAsequencing in different injury conditions compared to untreated cells F) Pooled injury curve fits including the scaled injury parameters steatosis, mitochondrial membrane potential alterations and number of DEGs from RNA sequencing. Injury scores were normalized to PNPLA3-wt conditions for which no hits represented 0% and all hits represent 100%.
    Figure Legend Snippet: A) Schematic of the multi-hit MASLD model in iPSC-derived hepatocytes and respective injury trajectories. B) Representative fluorescence microscopic images of HLCs cumulatively exposed to Oleic Acid and Palmitic Acid (OA/PA), Resistin and Myostatin (Res/Myo) and peripheral blood mono-nuclear cells (PBMCs) indicated as respective injury hit models and stained with LipidSpot and Mitotracker Red. C) Quantification of steatotic area normalized to respective Mitotracker area in percent. Dots represent independent wells. Tukey-Post Hoc analysis to test for significance. D) Quantification of Mitotracker signal intensity, normalized to untreated cells. Dots represent independent wells. Wilcoxon test to test for significance. E) Number of differentially expressed genes from bulk RNAsequencing in different injury conditions compared to untreated cells F) Pooled injury curve fits including the scaled injury parameters steatosis, mitochondrial membrane potential alterations and number of DEGs from RNA sequencing. Injury scores were normalized to PNPLA3-wt conditions for which no hits represented 0% and all hits represent 100%.

    Techniques Used: Derivative Assay, Fluorescence, Staining, Membrane, RNA Sequencing



    Similar Products

    recombinant myostatin  (MedChemExpress)
    93
    MedChemExpress recombinant myostatin
    Recombinant Myostatin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant myostatin/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    recombinant myostatin - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    recombinant human gdf8  (R&D Systems)
    93
    R&D Systems recombinant human gdf8
    Recombinant Human Gdf8, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human gdf8/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant human gdf8 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    recombinant myostatin  (PeproTech)
    90
    PeproTech recombinant myostatin
    A) Schematic of the multi-hit MASLD model in iPSC-derived hepatocytes and respective injury trajectories. B) Representative fluorescence microscopic images of HLCs cumulatively exposed to Oleic Acid and Palmitic Acid (OA/PA), <t>Resistin</t> and Myostatin (Res/Myo) and peripheral blood mono-nuclear cells (PBMCs) indicated as respective injury hit models and stained with LipidSpot and Mitotracker Red. C) Quantification of steatotic area normalized to respective Mitotracker area in percent. Dots represent independent wells. Tukey-Post Hoc analysis to test for significance. D) Quantification of Mitotracker signal intensity, normalized to untreated cells. Dots represent independent wells. Wilcoxon test to test for significance. E) Number of differentially expressed genes from bulk RNAsequencing in different injury conditions compared to untreated cells F) Pooled injury curve fits including the scaled injury parameters steatosis, mitochondrial membrane potential alterations and number of DEGs from RNA sequencing. Injury scores were normalized to PNPLA3-wt conditions for which no hits represented 0% and all hits represent 100%.
    Recombinant Myostatin, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant myostatin/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant myostatin - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mouse myeloma cell line  (R&D Systems)
    94
    R&D Systems mouse myeloma cell line
    A) Schematic of the multi-hit MASLD model in iPSC-derived hepatocytes and respective injury trajectories. B) Representative fluorescence microscopic images of HLCs cumulatively exposed to Oleic Acid and Palmitic Acid (OA/PA), <t>Resistin</t> and Myostatin (Res/Myo) and peripheral blood mono-nuclear cells (PBMCs) indicated as respective injury hit models and stained with LipidSpot and Mitotracker Red. C) Quantification of steatotic area normalized to respective Mitotracker area in percent. Dots represent independent wells. Tukey-Post Hoc analysis to test for significance. D) Quantification of Mitotracker signal intensity, normalized to untreated cells. Dots represent independent wells. Wilcoxon test to test for significance. E) Number of differentially expressed genes from bulk RNAsequencing in different injury conditions compared to untreated cells F) Pooled injury curve fits including the scaled injury parameters steatosis, mitochondrial membrane potential alterations and number of DEGs from RNA sequencing. Injury scores were normalized to PNPLA3-wt conditions for which no hits represented 0% and all hits represent 100%.
    Mouse Myeloma Cell Line, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse myeloma cell line/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    mouse myeloma cell line - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    recombinant human myostatin  (R&D Systems)
    90
    R&D Systems recombinant human myostatin
    A) Schematic of the multi-hit MASLD model in iPSC-derived hepatocytes and respective injury trajectories. B) Representative fluorescence microscopic images of HLCs cumulatively exposed to Oleic Acid and Palmitic Acid (OA/PA), <t>Resistin</t> and Myostatin (Res/Myo) and peripheral blood mono-nuclear cells (PBMCs) indicated as respective injury hit models and stained with LipidSpot and Mitotracker Red. C) Quantification of steatotic area normalized to respective Mitotracker area in percent. Dots represent independent wells. Tukey-Post Hoc analysis to test for significance. D) Quantification of Mitotracker signal intensity, normalized to untreated cells. Dots represent independent wells. Wilcoxon test to test for significance. E) Number of differentially expressed genes from bulk RNAsequencing in different injury conditions compared to untreated cells F) Pooled injury curve fits including the scaled injury parameters steatosis, mitochondrial membrane potential alterations and number of DEGs from RNA sequencing. Injury scores were normalized to PNPLA3-wt conditions for which no hits represented 0% and all hits represent 100%.
    Recombinant Human Myostatin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human myostatin/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    recombinant human myostatin - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    recombinant myostatin  (R&D Systems)
    93
    R&D Systems recombinant myostatin
    A) Schematic of the multi-hit MASLD model in iPSC-derived hepatocytes and respective injury trajectories. B) Representative fluorescence microscopic images of HLCs cumulatively exposed to Oleic Acid and Palmitic Acid (OA/PA), <t>Resistin</t> and Myostatin (Res/Myo) and peripheral blood mono-nuclear cells (PBMCs) indicated as respective injury hit models and stained with LipidSpot and Mitotracker Red. C) Quantification of steatotic area normalized to respective Mitotracker area in percent. Dots represent independent wells. Tukey-Post Hoc analysis to test for significance. D) Quantification of Mitotracker signal intensity, normalized to untreated cells. Dots represent independent wells. Wilcoxon test to test for significance. E) Number of differentially expressed genes from bulk RNAsequencing in different injury conditions compared to untreated cells F) Pooled injury curve fits including the scaled injury parameters steatosis, mitochondrial membrane potential alterations and number of DEGs from RNA sequencing. Injury scores were normalized to PNPLA3-wt conditions for which no hits represented 0% and all hits represent 100%.
    Recombinant Myostatin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant myostatin/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant myostatin - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    A) Schematic of the multi-hit MASLD model in iPSC-derived hepatocytes and respective injury trajectories. B) Representative fluorescence microscopic images of HLCs cumulatively exposed to Oleic Acid and Palmitic Acid (OA/PA), Resistin and Myostatin (Res/Myo) and peripheral blood mono-nuclear cells (PBMCs) indicated as respective injury hit models and stained with LipidSpot and Mitotracker Red. C) Quantification of steatotic area normalized to respective Mitotracker area in percent. Dots represent independent wells. Tukey-Post Hoc analysis to test for significance. D) Quantification of Mitotracker signal intensity, normalized to untreated cells. Dots represent independent wells. Wilcoxon test to test for significance. E) Number of differentially expressed genes from bulk RNAsequencing in different injury conditions compared to untreated cells F) Pooled injury curve fits including the scaled injury parameters steatosis, mitochondrial membrane potential alterations and number of DEGs from RNA sequencing. Injury scores were normalized to PNPLA3-wt conditions for which no hits represented 0% and all hits represent 100%.

    Journal: bioRxiv

    Article Title: Dissecting compounded hepatocyte injury in a model of MASLD progression from human induced pluripotent stem cells

    doi: 10.1101/2024.10.10.617610

    Figure Lengend Snippet: A) Schematic of the multi-hit MASLD model in iPSC-derived hepatocytes and respective injury trajectories. B) Representative fluorescence microscopic images of HLCs cumulatively exposed to Oleic Acid and Palmitic Acid (OA/PA), Resistin and Myostatin (Res/Myo) and peripheral blood mono-nuclear cells (PBMCs) indicated as respective injury hit models and stained with LipidSpot and Mitotracker Red. C) Quantification of steatotic area normalized to respective Mitotracker area in percent. Dots represent independent wells. Tukey-Post Hoc analysis to test for significance. D) Quantification of Mitotracker signal intensity, normalized to untreated cells. Dots represent independent wells. Wilcoxon test to test for significance. E) Number of differentially expressed genes from bulk RNAsequencing in different injury conditions compared to untreated cells F) Pooled injury curve fits including the scaled injury parameters steatosis, mitochondrial membrane potential alterations and number of DEGs from RNA sequencing. Injury scores were normalized to PNPLA3-wt conditions for which no hits represented 0% and all hits represent 100%.

    Article Snippet: To account for inter-organ signaling in our model, we tested recombinant resistin and myostatin (both Peprotech), both using 100 ng/ml concentration.

    Techniques: Derivative Assay, Fluorescence, Staining, Membrane, RNA Sequencing